What Circle's surge signals for the crypto IPO market
To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here.
Dan Lynch who is the equities and head of market inside. And one of the amazing areas that we've been tracking is the not just market reception to some of the strategic plays around cryptocurrency, but the other potential players that are still waiting in the wings to make a market entry. Circle was successful, but are there others that are in the crypto landscape, either platform or crypto touching and holding that you think could receive a solid market reception here?
Sure. So, Circle's IPO was really this big vote of confidence for the crypto and stable coin industry at large. And they really timed it well when you think of some of the bigger macro pieces at play. You have a crypto friendly administration in place. There's stable coin legislation out now that is really legitimizes stable coin. And then you have some of the biggest banks and retailers in the world talking about launching their own coins. Coinbase is now an S&P 500 company. So all these things are tailwinds to support these companies. When you look at others that might follow, Gemini is one that has confidentially filed. But several other of the top players in the private markets are continuing to grow. You know, Kraken, we just talked to the co-CEO there. Ripple and others are really growing in the private markets. And another lens on that is, you know, this idea of how tokenization can play a role in broadening access to the private markets. And that's something that the SEC chairman actually talked about this morning.
It's going to be fascinating to see how many of those companies are able to leverage this moment and this momentum and perhaps appeal to some of the investors in public equity landscape right now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Mizuho Cuts Northern Oil and Gas (NOG) PT to $32, Keeps Neutral Rating
Northern Oil and Gas Inc. (NYSE:NOG) is one of the most undervalued stocks to buy and hold for 3 years. On July 16, Mizuho lowered its price target for Northern Oil and Gas/NOG to $32 from $33, while maintaining a Neutral rating on the shares. The adjustment came as part of Mizuho's Q2 preview, as the firm anticipates NOG will reduce its 2025 capital expenditure budget and volume guidance due to decreased activity. The company achieved a record Adjusted EBITDA of ~$435 million in Q1 2025. Total average daily production reached ~ 135,000 BOE per day, which was a 2.5% increase sequentially and a 13% increase year-over-year. Oil production remained flat at ~79,000 barrels per day compared to the last quarter, while gas production contributed 42% to the mix, which was up 6.5% sequentially and 14% year-over-year. An aerial view of an oil and gas platform in the middle of the ocean, representing the massive resources harvested by the company. Capital expenditures in Q1 were ~$250 million, with 57% allocated to the Permian Basin. Northern Oil and Gas operates with a flexible model for capital allocation and has demonstrated strong financial performance, including 21 consecutive quarters of positive free cash flow, which total over $1.7 billion since 2020. Over 60% of its expected 2025 production is hedged. Northern Oil and Gas Inc. (NYSE:NOG) is an independent energy company that acquires, explores, exploites, develops, and produces crude oil and natural gas properties in the US. While we acknowledge the potential of NOG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
National Bank Downgrades Centerra Gold (CGAU) PT to C$14.75, Keeps Outperform Rating
Centerra Gold Inc. (NYSE:CGAU) is one of the cheap Canadian stocks to buy now. On July 16, National Bank adjusted its price target for Centerra Gold and lowered it from C$15.25 to C$14.75. Despite the slight downgrade, the bank maintained an Outperform rating on the shares and signaled continued confidence in Centerra Gold's prospects. In Q1 2025, the company showed gold production of ~60,000 ounces and copper production of 12 million pounds. The company ended the quarter with a strong cash position of $608 million. Adjusted net earnings for Q1 2025 were $26 million, or $0.13 per share. Sales included over 61,000 ounces of gold at an average realized price of $2,554 per ounce, and 12.1 million pounds of copper at an average realized price of $3.80 per pound. A closeup image of a miner holding a pile of gold nuggets, a representation of the company's royalty. Molybdenum sales reached ~4.2 million pounds at an average price of $21.59 per pound. Consolidated All-In Sustaining Costs on a byproduct basis were $1,491 per ounce. The company generated $10 million in free cash flow for the quarter, with Mount Milligan contributing $39 million from operations and $27 million in free cash flow, and Oksut contributing $50 million from operations and $42 million in free cash flow. Centerra Gold Inc. (NYSE:CGAU) is an energy company that acquires, explores, develops, and operates gold and copper properties in North America, Turkey, and internationally. It also explores for molybdenum deposits. While we acknowledge the potential of CGAU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO Capital adjusted its price target for Sarepta to $25 from $50, while maintaining a Market Perform rating. The decision was made as a response to the temporary pause in Sarepta's ELEVIDYS program. BMO Capital views this pause as an optimal decision, as refusal to comply with the FDA could lead to regulatory risks across Sarepta's programs and hinder ELEVIDYS' uptake. The temporary halt in ELEVIDYS shipments in the US began at the close of business on July 22 to allow Sarepta and the FDA to complete the safety labeling update process following a patient death linked to acute liver failure and other safety concerns. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. In Q1 2025, the company reported total net product revenue of $612 million, representing a 70% growth over the same quarter last year. ELEVIDYS revenue saw a 180% increase year-over-year and reached $375 million. The PMO (peptide-conjugated phosphorodiamidate morpholino oligomer) franchise revenue increased by 5% over the prior year and reached $237 million. Total revenues for the quarter were $745 million, which was an 80% increase year-over-year. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
